<article>China&#8217;s early-stage investor <a href="https://www.dealstreetasia.com/tag/Morningside-Venture-Capital/">Morningside Venture Capital</a> has led a $40-million Series A investment in gene therapy company Apic Bio, which is developing treatment options for patients with rare genetic diseases.</article>

China&#8217;s early-stage investor <a href="https://www.dealstreetasia.com/tag/Morningside-Venture-Capital/">Morningside Venture Capital</a> has led a $40-million Series A investment in gene therapy company Apic Bio, which is developing treatment options for patients with rare genetic diseases.
The round was joined by existing backers, The Alpha-1 Project (TAP) and A1ATD Investors, and new investor the ALS Investment Fund, according to a release.
Jason Dinges from Morningside will join the Apic Bio board and Felix von Coerper from the ALS Investment Fund will become a board observer.
Launched in August 2017, Apic Bio is a spinoff from the University of Massachusetts Medical School. It is developing treatment options for rare, devastating neurological and liver diseases. Its current pipeline focuses on new and effective treatments for Alpha-1 Antitrypsin Deficiency (Alpha-1, or AATD) and genetic Amyotrophic Lateral Sclerosis (ALS).
The company said it will use the funding raised to support further discovery efforts and advance its APB-101, APB-102 as well as preclinical Alpha-1 and ALS programs.
Founded in 1992, Morningside closed its maiden RMB-denominated fund at its $140-million hard cap in March last year, backed by a host of big investors including China Merchants Ventures, national industrial guidance fund Zhongjin Qiyuan, Tencent and Xiaomi.
According to CrunchBase data, Morningside Venture has assets worth $1.7 billion under management, including four USD funds and one RMB fund.
Recently, the VC firm raised $593 million for two separate vehicles, according to a filing with the US Securities and Exchange Commission (SEC).
Also Read: 
<a href="https://www.dealstreetasia.com/stories/morningside-usd-fund-108766/">China’s Morningside Venture Capital raises $1b USD-denominated fund</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/chinas-morningside-venture-capital-raises-593m-for-two-new-funds-107903/">China’s Morningside Venture Capital raises $593m for two new funds </a>

Morningside Venture Capital led $40-million Series A investment in gene therapy company Apic Bio, developing treatment options for patients with rare genetic diseases.

China's Morningside leads $40m funding in gene therapy developer Apic Bio

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

China's Morningside leads $40m funding in gene therapy developer Apic Bio

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief